BIGBEAR
PHARMACEUTICAL
Repotrectinib potently and selectively inhibits the abnormally activated kinase signaling pathways of ROS1 and NTRK, effectively overcomes resistance mutations to conventional targeted therapies, and exhibits favorable central nervous system penetration.
AuthenticGuaranteeFast DeliveryPrivacy Repotrectinib, a targeted drug for ROS1-positive non-small cell lung cancer, provides relief, but its potential side effects require timely detection ···【More】
Update: 10 Mar,2026Source: BigbearViews: 190
Repotrectinib has demonstrated breakthrough therapeutic efficacy against specific gene-mutant lung cancers, providing an important treatment option fo···【More】
Update: 10 Mar,2026Source: BigbearViews: 206
Repotrectinib, a novel kinase inhibitor, offers a new treatment option for certain lung cancer patients. Understanding its indications, contraindicati···【More】
Update: 10 Mar,2026Source: BigbearViews: 179
On November 16, 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved ripretinib (Augtyro) for the treatm···【More】
Update: 03 Mar,2026Source: BigbearViews: 193
Ripretinib (Augtyro) is a next-generation targeted anticancer drug developed by Bristol-Myers Squibb (BMS), offering a new precision treatment option ···【More】
Update: 03 Mar,2026Source: BigbearViews: 180
Repotrectinib is a novel, oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) primarily used to treat advanced solid tumors harboring s···【More】
Update: 03 Mar,2026Source: BigbearViews: 213
Repotrectinib, an innovative ROS1 and NTRK-targeting inhibitor, can simultaneously inhibit multiple oncogenic targets, exhibiting broad-spectrum anti-···【More】
Update: 03 Mar,2026Source: BigbearViews: 178
Repotrectinib is a new generation of targeted anticancer drug developed by Bristol-Myers Squibb (BMS), providing a new option for precision treatment ···【More】
Update: 03 Mar,2026Source: BigbearViews: 205
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
